Erythropoiesis-stimulating agents

Phase 3Small molecule

Erythropoiesis-stimulating agents is one of 87 small molecule programs targeting Intelligence. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

AnemiaPhase 3

Active, not recruiting

Myelodysplastic SyndromesPreclinical

Active, not recruiting

Competition

Competitive Landscape

272 competitors in Anemia

#DrugCompanyPhaseTrials

Methoxy Polyethylene Glycol-Ep

Roche

Phase 3

36 2

Fludara

Sanofi

Phase 3

1 3

Soliris

AstraZeneca

Phase 3

1 4

Sandostatin

Sun Pharma

Phase 3

1 5

Alkeran

AApotex Inc.

Phase 3

1 6

Imbruvica

PPharmacyclics LLC.

Phase 3

1 7

Ferrous Sulphate

VVifor Pharma

Phase 3

3 8

Sodium Nitroprusside

WWatson Pharmaceuticals

Phase 3

1 9

Epoetin

Roche

Phase 3

5 10

Epoetin Hospira

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Anemia

NCT06901505

Clinical

Trials by Indication[1]

Myelodysplastic Syndromes2 trials

A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06851065·418 enrolled

A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07465029·1,300 enrolled

Effectiveness1 trial

A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06971185·430 enrolled

Intelligence1 trial

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

Terminated·VVifor Fresenius Medical Care Renal Pharma·N/A·NCT03214627·88 enrolled

Anemia1 trial

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Active, not recruiting·AAkebia Therapeutics·Phase 3·NCT06901505·353 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Erythropoiesis-stimulating agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Erythropoiesis-stimulating agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Erythropoiesis-stimulating agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Erythropoiesis-stimulating agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Myelodysplastic Syndromes2 trials

Effectiveness1 trial

Intelligence1 trial

Anemia1 trial

References

Drug Info

Quick Facts

Related News